Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11004045rdf:typepubmed:Citationlld:pubmed
pubmed-article:11004045lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0006684lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0020538lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0543467lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0010280lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0022860lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0028005lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C1579762lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:11004045lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:11004045pubmed:issue4lld:pubmed
pubmed-article:11004045pubmed:dateCreated2000-10-18lld:pubmed
pubmed-article:11004045pubmed:abstractTextWe compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension. A prospective, randomized open labeled clinical trial was designed to compare the incidence of breakthrough hypertension (systolic blood pressure [SBP] > 140 mm Hg) and adverse effects (hypotension, tachycardia, and bradycardia) between the two drug combinations. Secondarily, the effects of the drugs on SBP, mean blood pressure, and diastolic blood pressure were evaluated over the course of the study. Forty-two patients received enalaprilat 1.25 mg IV at dural closure followed by either multidose nicardipine 2 mg IV or labetalol 5 mg IV to maintain the SBP below 140 mm Hg. SBP was similarly controlled in both groups. There was a marginally smaller incidence of failures and adverse effects with labetalol. Blood pressure profiles were similar for both groups.lld:pubmed
pubmed-article:11004045pubmed:languageenglld:pubmed
pubmed-article:11004045pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11004045pubmed:statusMEDLINElld:pubmed
pubmed-article:11004045pubmed:monthOctlld:pubmed
pubmed-article:11004045pubmed:issn0003-2999lld:pubmed
pubmed-article:11004045pubmed:authorpubmed-author:LeungDDlld:pubmed
pubmed-article:11004045pubmed:authorpubmed-author:FerriEElld:pubmed
pubmed-article:11004045pubmed:authorpubmed-author:MelendezJ AJAlld:pubmed
pubmed-article:11004045pubmed:authorpubmed-author:PratilaMMlld:pubmed
pubmed-article:11004045pubmed:authorpubmed-author:VeroneseAAlld:pubmed
pubmed-article:11004045pubmed:authorpubmed-author:BroadCClld:pubmed
pubmed-article:11004045pubmed:authorpubmed-author:KrossR ARAlld:pubmed
pubmed-article:11004045pubmed:issnTypePrintlld:pubmed
pubmed-article:11004045pubmed:volume91lld:pubmed
pubmed-article:11004045pubmed:ownerNLMlld:pubmed
pubmed-article:11004045pubmed:authorsCompleteYlld:pubmed
pubmed-article:11004045pubmed:pagination904-9lld:pubmed
pubmed-article:11004045pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:meshHeadingpubmed-meshheading:11004045...lld:pubmed
pubmed-article:11004045pubmed:year2000lld:pubmed
pubmed-article:11004045pubmed:articleTitleA comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery.lld:pubmed
pubmed-article:11004045pubmed:affiliationDepartment of Anesthesiology and Critical Care Medicine and Biostatistics, Memorial Sloan-Kettering Cancer Center and Weil Medical College of Cornell University, New York, New York, USA.lld:pubmed
pubmed-article:11004045pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11004045pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11004045pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11004045pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11004045lld:pubmed